Xanodyne Pharmaceuticals Inc., a Florence, Ky.-based drug company, has withdrawn registration for an $86.25 million IPO due to “market conditions.” It had planned to trade on the Nasdaq, with Morgan Stanley and Deutsche Bank Securities serving as co-lead underwriters.
